“We’re not a screening or tools company; we’re a drug discovery company.” Such is the adamant mantra of Kalypsys’ president and CEO John McKearn.

However, the screening technology and tools used by the San Diego-based company for its own drug discovery are apparently viewed as a valuable commodity. In June, the National Institutes of Health’s newly established Chemical Genomics Center selected Kalypsys to provide it with a suite of ultra-high throughput screening technologies in a deal that could be worth $30 million over the next four years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.